ES2102815T5 - Procedimiento para la obtencion de ectodominios nativos, oligomeros, glicosilados de proteinas de membrana virales, su utilizacion, en especial como vacuna contra el vih. - Google Patents
Procedimiento para la obtencion de ectodominios nativos, oligomeros, glicosilados de proteinas de membrana virales, su utilizacion, en especial como vacuna contra el vih.Info
- Publication number
- ES2102815T5 ES2102815T5 ES94904568T ES94904568T ES2102815T5 ES 2102815 T5 ES2102815 T5 ES 2102815T5 ES 94904568 T ES94904568 T ES 94904568T ES 94904568 T ES94904568 T ES 94904568T ES 2102815 T5 ES2102815 T5 ES 2102815T5
- Authority
- ES
- Spain
- Prior art keywords
- protein
- native
- ectodomines
- organization
- recovered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title abstract 3
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 108010065667 Viral Matrix Proteins Proteins 0.000 title abstract 2
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 4
- 108090000623 proteins and genes Proteins 0.000 abstract 4
- 102000004169 proteins and genes Human genes 0.000 abstract 4
- 230000008520 organization Effects 0.000 abstract 3
- 102000004190 Enzymes Human genes 0.000 abstract 2
- 108090000790 Enzymes Proteins 0.000 abstract 2
- 206010061598 Immunodeficiency Diseases 0.000 abstract 1
- 208000029462 Immunodeficiency disease Diseases 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 230000002068 genetic effect Effects 0.000 abstract 1
- 230000007813 immunodeficiency Effects 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 108020001580 protein domains Proteins 0.000 abstract 1
- 230000002797 proteolythic effect Effects 0.000 abstract 1
- 238000011084 recovery Methods 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
LA PRESENTE INVENCION SE REFIERE A UN PROCEDIMIENTO PARA LA RECUPERACION DE DOMINIOS NATIVOS DE PROTEINAS DE MEMBRANAS VIRALES, EN PARTICULAR NATIVAS, ES DECIR OLIGOMEROS Y ECTODOMINIOS GLICOSILADOS DE PROTEINA SUPERFICIAL GP 160 DEL VIRUS DE INMUNODEFICIENCIA HUMANA, QUE EN EL ORGANISMO ORIGINA EL SIDA (AQUIRED IMMUNE DEFICIENCY SYNDROME) EN BASE AL VIRUS HIV (HUMAN IMMUNODEFICIENCY VIRUS), ASI COMO A LOS DOMINIOS DE PROTEINA NATIVA RECUPERADOS MEDIANTE EL PROCESO, EN PARTICULAR ECTODOMINIOS NATIVOS DE GLICOPROTEINA HIV DE ENVUELTA CUYOS MONOMEROS DISPONEN DE UNA MOVILIDAD ELECTROFORETICA DE APROXIMADAMENTE 140 KD, Y SU UTILIZACION COMO VACUNA, EN PARTICULAR COMO VACUNA CONTRA HIV. UNA SECUENCIA DE NUCLEOTIDO QUE SE CODIFICA PARA UNA SECUENCIA DE RECONOCIMIENTO DE ENZIMAS PROTEOLITICAS SE INSERTA EN UN LUGAR APROPIADO DEL EJE QUE CODIFICA LA PROTEINA PRECURSORA DE LOS DOMINIOS DE PROTEINA A SER RECUPERADOS. DESPUES DE QUE EL MUTANTE GENETICO SE EXPRESA EN CELDAS EUCARIOTICAS, SE DIGIEREN CON UNA ENZIMA APROPIADA Y SE PURIFICA ENTONCES EL DOMINO DE PROTEINA A SER RECUPERADO.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4301017 | 1993-01-16 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES2102815T3 ES2102815T3 (es) | 1997-08-01 |
| ES2102815T5 true ES2102815T5 (es) | 2001-11-16 |
Family
ID=6478309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES94904568T Expired - Lifetime ES2102815T5 (es) | 1993-01-16 | 1994-01-12 | Procedimiento para la obtencion de ectodominios nativos, oligomeros, glicosilados de proteinas de membrana virales, su utilizacion, en especial como vacuna contra el vih. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6140059A (es) |
| EP (1) | EP0679187B2 (es) |
| JP (1) | JP3658690B2 (es) |
| AT (1) | ATE153380T1 (es) |
| DE (2) | DE4400659C2 (es) |
| DK (1) | DK0679187T4 (es) |
| ES (1) | ES2102815T5 (es) |
| GR (1) | GR3023717T3 (es) |
| WO (1) | WO1994016081A1 (es) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2781676B1 (fr) * | 1998-07-31 | 2004-04-02 | Pasteur Merieux Serums Vacc | Trimere du produit d'expression du gene env de hiv |
| AU2221600A (en) | 1998-12-31 | 2000-07-31 | Chiron Corporation | Improved expression of hiv polypeptides and production of virus-like particles |
| AU2487300A (en) * | 1998-12-31 | 2000-07-31 | Chiron Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| JP4776075B2 (ja) | 1998-12-31 | 2011-09-21 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | 改変ｈｉｖｅｎｖポリペプチド |
| US7935805B1 (en) * | 1998-12-31 | 2011-05-03 | Novartis Vaccines & Diagnostics, Inc | Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof |
| EP1214333A4 (en) * | 1999-09-17 | 2005-01-19 | Dana Farber Cancer Inst Inc | SOLUBLE STABILIZED GLYCOPROTEIN TRIMERS |
| US7179468B1 (en) | 2000-06-08 | 2007-02-20 | Cornell Research Foundation, Inc. | Antigen for developing neutralizing antibodies to human immunodeficiency virus |
| EP1411770A4 (en) * | 2001-07-05 | 2006-05-10 | Chiron Corp | POLYNUCLEOTIDES CODING FOR ANTIGENIC C-TYPE HIV POLYPEPTIDES, POLYPEPTIDES AND THEIR USE |
| EP2280074A3 (en) * | 2001-07-05 | 2011-06-22 | Novartis Vaccines and Diagnostics, Inc. | Polynucleotides encoding antigenic HIV type B and/or type C polypeptides, polypeptides and uses thereof |
| US20030170614A1 (en) * | 2001-08-31 | 2003-09-11 | Megede Jan Zur | Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof |
| CA2458995C (en) * | 2001-08-31 | 2013-04-30 | Chiron Corporation | Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof |
| WO2004101598A2 (en) * | 2003-05-09 | 2004-11-25 | Research Development Foundation | Insertion of furin protease cleavage sites in membrane proteins and uses thereof |
| US7358334B1 (en) | 2003-11-14 | 2008-04-15 | Jay W Chaplin | B cell-targeted toxins for humoral immune response reduction and methods of use thereof |
| US9216212B2 (en) | 2005-08-05 | 2015-12-22 | University Of Massachusetts | Virus-like particles as vaccines for paramyxovirus |
| US7951384B2 (en) * | 2005-08-05 | 2011-05-31 | University Of Massachusetts | Virus-like particles as vaccines for paramyxovirus |
| US8580270B2 (en) | 2008-09-30 | 2013-11-12 | University Of Massachusetts | Respiratory synctial virus (RSV) sequences for protein expression and vaccines |
| AU2010222942B2 (en) | 2009-03-10 | 2013-01-10 | Baylor Research Institute | Anti-CD40 antibodies and uses thereof |
| CN102770457A (zh) * | 2009-03-10 | 2012-11-07 | 贝勒研究院 | 靶向抗原呈递细胞的疫苗 |
| DK2406289T3 (en) * | 2009-03-10 | 2017-05-01 | Baylor Res Inst | ANTIGEN PRESENTING CELL TARGETED ANTIVIRUS VACCINES |
| AU2011230619C1 (en) | 2010-03-25 | 2016-06-23 | Oregon Health & Science University | CMV glycoproteins and recombinant vectors |
| CA2831294A1 (en) | 2011-03-25 | 2012-10-04 | Baylor Research Institute | Compositions and methods to immunize against hepatitis c virus |
| HUE037408T2 (hu) | 2011-06-10 | 2018-08-28 | Univ Oregon Health & Science | CMV glikoproteinek és rekombináns vektorok |
| US9402894B2 (en) | 2011-10-27 | 2016-08-02 | International Aids Vaccine Initiative | Viral particles derived from an enveloped virus |
| ES2631608T3 (es) | 2012-06-27 | 2017-09-01 | International Aids Vaccine Initiative | Variante de la glicoproteína Env del VIH-1 |
| EP2848937A1 (en) | 2013-09-05 | 2015-03-18 | International Aids Vaccine Initiative | Methods of identifying novel HIV-1 immunogens |
| US10058604B2 (en) | 2013-10-07 | 2018-08-28 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
| CN120939216A (zh) | 2014-01-13 | 2025-11-14 | 贝勒研究院 | 抗hpv和hpv相关的疾病的新疫苗 |
| EP3069730A3 (en) | 2015-03-20 | 2017-03-15 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
| US9931394B2 (en) | 2015-03-23 | 2018-04-03 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
| US10610585B2 (en) | 2017-09-26 | 2020-04-07 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and compositions for treating and preventing HIV |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3731874A1 (de) * | 1987-09-18 | 1989-03-30 | Schering Ag | Verfahren zur herstellung von peptiden durch spezifische spaltung von gentechnisch gewonnenen fusionsproteinen mit collagenasen |
| IL89567A0 (en) * | 1988-03-28 | 1989-09-10 | Univ Leland Stanford Junior | Mutated hiv envelope protein |
| CA2077753C (en) † | 1990-03-09 | 2000-02-29 | Nancy L. Haigwood | Purified gp120 composition retaining natural conformation |
| FR2676071B1 (fr) * | 1991-05-02 | 1994-11-18 | Transgene Sa | Nouveau variant gp160 non-clivable, soluble, de forme hybride. |
-
1994
- 1994-01-12 WO PCT/DE1994/000022 patent/WO1994016081A1/de not_active Ceased
- 1994-01-12 US US08/448,619 patent/US6140059A/en not_active Expired - Fee Related
- 1994-01-12 ES ES94904568T patent/ES2102815T5/es not_active Expired - Lifetime
- 1994-01-12 EP EP94904568A patent/EP0679187B2/de not_active Expired - Lifetime
- 1994-01-12 DK DK94904568T patent/DK0679187T4/da active
- 1994-01-12 AT AT94904568T patent/ATE153380T1/de not_active IP Right Cessation
- 1994-01-12 DE DE4400659A patent/DE4400659C2/de not_active Expired - Fee Related
- 1994-01-12 JP JP51558794A patent/JP3658690B2/ja not_active Expired - Fee Related
- 1994-01-12 DE DE59402827T patent/DE59402827D1/de not_active Expired - Fee Related
-
1997
- 1997-06-10 GR GR970401358T patent/GR3023717T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE59402827D1 (de) | 1997-06-26 |
| WO1994016081A1 (de) | 1994-07-21 |
| DE4400659C2 (de) | 1995-07-27 |
| JPH08505769A (ja) | 1996-06-25 |
| ES2102815T3 (es) | 1997-08-01 |
| GR3023717T3 (en) | 1997-09-30 |
| DK0679187T4 (da) | 2001-09-17 |
| EP0679187B2 (de) | 2001-07-04 |
| DK0679187T3 (da) | 1997-12-08 |
| DE4400659A1 (de) | 1994-07-21 |
| ATE153380T1 (de) | 1997-06-15 |
| US6140059A (en) | 2000-10-31 |
| EP0679187B1 (de) | 1997-05-21 |
| JP3658690B2 (ja) | 2005-06-08 |
| EP0679187A1 (de) | 1995-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2102815T5 (es) | Procedimiento para la obtencion de ectodominios nativos, oligomeros, glicosilados de proteinas de membrana virales, su utilizacion, en especial como vacuna contra el vih. | |
| AR069653A2 (es) | Variante de glucoamilasa original de aspergillus, una construccion de adn, un vector de expresion recombinante, una celula, un proceso para convertir almidon, uso de una variante de glucoamilasa para un proceso de la fermentacion y metodo para alterar la estabilidad termica. | |
| ATE451462T1 (de) | Klonierung und expression von htlv-iii-dns | |
| DE68924162D1 (de) | Stressproteine und verwendungen dafür. | |
| NO975546D0 (no) | Antigene gruppe B-streptokokk-type II- og type III-polysakkaridfragmenter med en 2,5-anhydro-D-mannose-terminal struktur samt en konjugatvaksine derav | |
| DK0909323T3 (da) | Helicobacter pylori-bakterioferritin | |
| ES2010727A6 (es) | Metodo para producir lineas celulares que producen anticuerpos monoclonales reactivos frente a determinantes antigenicos de gp110 o de p25 de hiv. | |
| DE69132902D1 (de) | Methoden zur identifizierung heterofunktionaler fusionsproteine | |
| ES8600938A1 (es) | Un procedimiento para preparar el antigeno de superficie de la hepatitis b | |
| CO4480058A1 (es) | Genes codificantes y procedimiento de expresion de una nueva enzima: ftalil amidasa | |
| BR9612422A (pt) | Pseudo-partìculas virais recombinantes, composição, utilização de pseudo-partìculas, e, processo de estimulação in vitro de respostas t citotóxicas de linfócitos provenientes de indivìduos atingidos por infecções virais ou tumorais. | |
| DE60027581D1 (de) | Design von immunogene | |
| NO178870C (no) | Fremgangsmåte for fremstilling av modifisert Eglin B eller C samt DNA, ekspresjonsvektor og vertsmikroorganisme | |
| KR890008166A (ko) | 융합 단백질의 선택적 분해 방법 | |
| ES2061524T3 (es) | Un vector plasmidico para la expresion en bacillus y empleado para la clonacion del gen estructural que codifica la hormona de crecimiento humana y un metodo para la produccion de la hormona. | |
| ATE144429T1 (de) | Impfstoff | |
| ES8801958A1 (es) | Un procedimiento para la determinacion de virus de sida | |
| DK0575462T3 (da) | Fremgangsmåde til fremstilling af chymosin | |
| GT198304126A (es) | Produccion de proteinas del virus de herpes simplex | |
| NO874391L (no) | Nye gjaerekspresjonsvektorer for ifn-omega samt fremgangsmaate for fremstilling og anvendelse derav. | |
| FI934079L (fi) | Menetelmä fuusioproteiinin valmistamiseksi | |
| TH4073A (th) | รีคอมบิแนนท์ ไวรัส |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 679187 Country of ref document: ES |